Joint Nordic Procurement of Pharmaceuticals - 2025 - NF2.1301.a
Ordregiver: Amgros I/S
- Offentliggjort
- 11 juni 2025
- Anslået værdi
- 225.775.606 €
- Udførelsessted
- DK011
- Procedure
- Offentligt udbud
- Bekendtgørelsesnummer
- 00376656-2025-01
- Reference
- 294fa2d3-d4a2-4861-b555-052a3e0ef9cd
- Officiel kilde
- Officiel kilde
CPV-koder
- 33600000Lægemidler
Beskrivelse
Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals in the countries. In Denmark certain pharmaceuticals are resold to the Faroe Island and Greenland. Under this tender group, the pharmaceuticals are tendered under each lot no. for the purpose of supplying the Contracting Authorities as 2 markets (Norway as 1 market and Denmark and Iceland as 1 market) see the tender specification. The obligation to deliver the pharmaceuticals in Iceland is subject to the precondition that the supplier obtains an exemption regarding printed labels and leaflets. If the supplier does not obtain such exemption the agreement will only apply to Denmark and Norway, see the Framework agreement section 2.2.1 and Appendix 6.
Delkontrakter (20)
| Delkontrakt | Beskrivelse | CPV-kode | Beløb |
|---|---|---|---|
| 1 | Lot No. 1 | 33600000 Lægemidler | 13.922.377 € |
| 2 | Lot No. 2 | 33600000 Lægemidler | 6.185.148 € |
| 3 | Lot No. 3 | 33600000 Lægemidler | 135.757.116 € |
| 4 | Lot No. 4 | 33600000 Lægemidler | 37.864.841 € |
| 5 | Lot No. 5 | 33600000 Lægemidler | 259.953 € |
| 6 | Lot No. 6 | 33600000 Lægemidler | 87.971 € |
| 7 | Lot No. 7 | 33600000 Lægemidler | 10.319.567 € |
| 8 | Lot No. 8 | 33600000 Lægemidler | 427.251 € |
| 9 | Lot No. 9 | 33600000 Lægemidler | 740.643 € |
| 10 | Lot No. 10 | 33600000 Lægemidler | 137.747 € |
| 11 | Lot No. 11 | 33600000 Lægemidler | 2.599.196 € |
| 12 | Lot No. 12 | 33600000 Lægemidler | 892.564 € |
| 13 | Lot No. 13 | 33600000 Lægemidler | 3.037.641 € |
| 14 | Lot No. 14 | 33600000 Lægemidler | 451.849 € |
| 15 | Lot No. 15 | 33600000 Lægemidler | 834.853 € |
| 16 | Lot No. 16 | 33600000 Lægemidler | 740.071 € |
| 17 | Lot No. 17 | 33600000 Lægemidler | 3.071.346 € |
| 18 | Lot No. 18 | 33600000 Lægemidler | 2.716.354 € |
| 19 | Lot No. 19 | 33600000 Lægemidler | 5.161.866 € |
| 20 | Lot No. 20 | 33600000 Lægemidler | 567.292 € |
Tildelingskriterier
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
- Pris — Price is not the only award criterion and all criteria are stated only in the procurement documents.
Tildelinger
| Tildelt til | Beløb | Dato |
|---|---|---|
| EQL Pharma AB | 12.777.840 € | 30 september 2024 |
| Fresenius Kabi, Filial af Fresenius Kabi AB, Sverige | 3.759.200 € | 30 september 2024 |
| FrostPharma AB | 3.614.480 € | 30 september 2024 |
| STADA Nordic ApS | 3.180.080 € | 30 september 2024 |
| B. Braun Medical AS | 1.890.000 € | 30 september 2024 |
| B. Braun Medical AS | 1.595.000 € | 30 september 2024 |
| Navamedic AB | 1.570.229 € | 30 september 2024 |
| Hameln Pharma ApS | 1.534.695 € | 30 september 2024 |
| Orion Pharma A/S | 906.200 € | 30 september 2024 |
| Navamedic AB | 640.700 € | 30 september 2024 |
Officielle publikationer
Andre udbud fra Amgros I/S
- Amgros 2027 1.1174.a
- Amgros 2026 1.1581.a
- Amgros 2027 1.1171.a
- OPLYSNING OM INDGÅELSE AF AMGROS’ IBRUGTAGNINGSAFTALER PÅ UDVALGTE LÆGEMIDLER I 2026 Q4
- Markedsdialog om Amgros' kommende udbud på infusions-/injektionsvæsker med indhold af kulhydrater og elektrolytter.
- Amgros 2027 1.1042.b
- Amgros 2027 1.1073.a
- Amgros 2027 1.1051.b
- Amgros 2027 1.1490.a
- Amgros 2027 1.1152.a
Ofte stillede spørgsmål
- Hvad er den anslåede værdi af dette udbud?
- Den anslåede værdi offentliggjort af ordregiveren er 225.775.606 €.
- Hvem er ordregiver for dette udbud?
- Ordregiveren er Amgros I/S (Danmark).
- Hvordan kan jeg byde på offentlige udbud i Danmark?
- Tilbud afgives via den officielle udbudsportal i Danmark. El Vínculo hjælper dig med at finde udbud og analysere dokumenterne; afgivelsen sker altid hos den officielle kilde.
Få besked om udbud som dette
Opret en gratis konto, og modtag hver dag nye udbud i Danmark, der matcher din virksomhed.
Opret en gratis konto, og modtag hver dag nye udbud i Danmark, der matcher din virksomhed.